Date | Chamber | Action |
1/11/2005 | House | Session Sine Die |
30 ILCS 105/5.595 new |
320 ILCS 25/3.15 | from Ch. 67 1/2, par. 403.15 |
320 ILCS 25/4.5 new |
Fiscal Note (Department of Public Aid) | |
There will be no additional appropriated cost to the Department of Public Aid. Assuming rebates for prescriptions paid by Medicaid will continue to be deposited into the Drug Rebate Fund, the only potential impact IDPA could be a reduction of the "Best Price" charged by a manufacturer which could reduce the level of federal rebates. There will be administrative costs associated with operating this program. Either a complicated tracking system will need to be developed and staffed, or an outside entity will need to be hired. Additionally, IDOR will pay all but $1.00 for generic and $4.00 for name brand drug prescriptions. Without knowing the number of rule additions or the rebate agreements negotiated, the additional cost of the legislation could not be defined. |
Date | Chamber | Action | 2/21/2003 | House | Filed with the Clerk by Rep. Elizabeth Coulson | 2/21/2003 | House | First Reading | 2/21/2003 | House | Referred to Rules Committee | 2/26/2003 | House | Assigned to Revenue Committee | 3/11/2003 | House | Fiscal Note Filed | 3/13/2003 | House | Rule 19(a) / Re-referred to Rules Committee | 1/11/2005 | House | Session Sine Die |
Back To Top |